Several months after rebranding, an old Martin Skhreli company touts promising pivotal data in a rare kidney disorder

If all goes well at the FDA, Calliditas could cross the finish line with its inflammatory kidney disease treatment Nefecon next month. But Travere Therapeutics isn’t far behind — and on Monday, the former Martin Shkreli company unveiled some promising pivotal data that may give Calliditas a run for its money.